The type 1 FLT3 inhibitor midostaurin is approved by the EMA and the US Food and Drug Administration (FDA) for upfront therapy as well as remission maintenance in patients with FLT3-mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.